ARDS
Aridis Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.00
+0.00 (+0.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 10 |
Stock Information
| Shares Outstanding | 44.57M |
| Total Debt | $4.84M |
| Cash Equivalents | $35K |
| Revenue | $22.36M |
| Net Income | $-1.14M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $9K |
| EPS (TTM) | $-0.02 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.81M |
| Sales | $22.36M |
| Income | $-1.14M |
| Book/sh | $-0.27 |
| Cash/sh | $0.00 |
| Employees | 37 |
Financial Ratios
| Quick Ratio | 0.03 |
| Current Ratio | 0.23 |
Returns & Margins
| ROA | -4.40% |
| Gross Margin | 23.28% |
| Operating Margin | -208.39% |
| Profit Margin | -5.11% |
Ownership
| Institutional Ownership | 11.44% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.00 |
| P/S | 0.00 |
| P/B | -0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.00 |
| RSI | 50.00 |
| ATR | 0.0011 |
| Shares Float | 40.31M |
| Short Float | 6.80% |
| Short Ratio | 0.22 |
| Volatility | 3599.34 |
Performance History
| Week | -87.88% |
| Month | +0.00% |
| Quarter | +0.00% |
| 6 Months | +0.00% |
| YTD | +0.00% |
| Year | +100.00% |
| 3 Years | -99.89% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-03 | $0.00 | 0 |
| 2026-06-02 | $0.00 | 666 |
| 2026-06-01 | $0.00 | 0 |
| 2026-05-29 | $0.00 | 0 |
| 2026-05-28 | $0.00 | 11,103 |
| 2026-05-27 | $0.00 | 0 |
| 2026-05-26 | $0.00 | 0 |
| 2026-05-22 | $0.00 | 3,145 |
| 2026-05-21 | $0.00 | 722 |
| 2026-05-20 | $0.00 | 51,200 |
| 2026-05-19 | $0.00 | 755 |
| 2026-05-18 | $0.00 | 2,000 |
| 2026-05-15 | $0.00 | 5,100 |
| 2026-05-14 | $0.00 | 12,110 |
| 2026-05-13 | $0.00 | 518 |
| 2026-05-12 | $0.00 | 1,004 |
| 2026-05-11 | $0.00 | 100,857 |
| 2026-05-08 | $0.00 | 1,725 |
| 2026-05-07 | $0.00 | 410 |
| 2026-05-06 | $0.00 | 330 |
| 2026-05-05 | $0.00 | 2,550 |
| 2026-05-04 | $0.00 | 550 |
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on ARDS.
Period:
Loading...
Income Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $29,993,000 | $42,711,000 |
| Other Income Expense | $-257,000 | $763,000 |
| Other Non Operating Income Expenses | $-257,000 | $41,000 |
| Net Non Operating Interest Income Expense | $-121,000 | $-245,000 |
| Total Other Finance Cost | $121,000 | $245,000 |
| Operating Expense | $29,993,000 | $42,711,000 |
| Other Operating Expenses | $-3,091,000 | $-1,535,000 |
| General And Administrative Expense | $7,161,000 | $7,310,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-30,371,000 | $-42,193,000 |
| Net Interest Income | $-121,000 | $-245,000 |
| Normalized Income | $-30,371,000 | $-42,915,000 |
| Net Income From Continuing And Discontinued Operation | $-30,371,000 | $-42,193,000 |
| Total Operating Income As Reported | $-29,993,000 | $-42,711,000 |
| Net Income Common Stockholders | $-30,371,000 | $-46,320,000 |
| Net Income | $-30,371,000 | $-42,193,000 |
| Net Income Including Noncontrolling Interests | $-30,371,000 | $-42,193,000 |
| Net Income Continuous Operations | $-30,371,000 | $-42,193,000 |
| Pretax Income | $-30,371,000 | $-42,193,000 |
| Special Income Charges | $0 | $722,000 |
| Operating Income | $-29,993,000 | $-42,711,000 |
| Earnings From Equity Interest | - | $0 |
| Per Share | ||
| Diluted EPS | $-1.62 | $-3.85 |
| Basic EPS | $-1.62 | $-3.85 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-29,506,000 | $-42,998,000 |
| Total Unusual Items | $0 | $722,000 |
| Total Unusual Items Excluding Goodwill | $0 | $722,000 |
| Reconciled Depreciation | $487,000 | $435,000 |
| EBITDA (Bullshit earnings) | $-29,506,000 | $-42,276,000 |
| EBIT | $-29,993,000 | $-42,711,000 |
| Diluted Average Shares | $18,777,335 | $12,291,600 |
| Basic Average Shares | $18,777,335 | $12,291,600 |
| Diluted NI Availto Com Stockholders | $-30,371,000 | $-46,320,000 |
| Otherunder Preferred Stock Dividend | $0 | $4,127,000 |
| Research And Development | $25,923,000 | $36,936,000 |
| Selling General And Administration | $7,161,000 | $7,310,000 |
| Other Gand A | $7,161,000 | $7,310,000 |
| Other Special Charges | - | $-722,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-24,249,000 | $-13,132,000 |
| Total Assets | $14,695,000 | $26,796,000 |
| Total Non Current Assets | $3,069,000 | $2,406,000 |
| Other Non Current Assets | $827,000 | $931,000 |
| Non Current Deferred Assets | $78,000 | $96,000 |
| Goodwill And Other Intangible Assets | $17,000 | $22,000 |
| Other Intangible Assets | $17,000 | $22,000 |
| Current Assets | $11,626,000 | $24,390,000 |
| Current Deferred Assets | $1,986,000 | $1,967,000 |
| Restricted Cash | $183,000 | $1,388,000 |
| Prepaid Assets | $3,341,000 | $2,700,000 |
| Receivables | $1,240,000 | $237,000 |
| Other Receivables | $240,000 | $237,000 |
| Accounts Receivable | $1,000,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $4,876,000 | $18,098,000 |
| Cash And Cash Equivalents | $4,876,000 | $18,098,000 |
| Debt | ||
| Total Debt | $6,130,000 | $5,978,000 |
| Long Term Debt And Capital Lease Obligation | $1,292,000 | $5,282,000 |
| Current Debt And Capital Lease Obligation | $4,838,000 | $696,000 |
| Current Debt | $4,300,000 | $696,000 |
| Long Term Debt | - | $5,282,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $38,927,000 | $39,906,000 |
| Total Non Current Liabilities Net Minority Interest | $2,029,000 | $6,558,000 |
| Non Current Deferred Liabilities | $737,000 | $913,000 |
| Current Liabilities | $36,898,000 | $33,348,000 |
| Other Current Liabilities | $15,000 | $110,000 |
| Current Deferred Liabilities | $20,173,000 | $20,838,000 |
| Current Notes Payable | $4,300,000 | $696,000 |
| Payables And Accrued Expenses | $11,872,000 | $11,704,000 |
| Payables | $2,308,000 | $5,240,000 |
| Accounts Payable | $2,308,000 | $5,240,000 |
| Other Non Current Liabilities | - | $363,000 |
| Equity | ||
| Common Stock Equity | $-24,232,000 | $-13,110,000 |
| Total Equity Gross Minority Interest | $-24,232,000 | $-13,110,000 |
| Stockholders Equity | $-24,232,000 | $-13,110,000 |
| Gains Losses Not Affecting Retained Earnings | $5,051,000 | $0 |
| Retained Earnings | $-195,666,000 | $-165,295,000 |
| Other | ||
| Ordinary Shares Number | $27,033,532 | $17,701,592 |
| Share Issued | $27,033,532 | $17,701,592 |
| Tangible Book Value | $-24,249,000 | $-13,132,000 |
| Invested Capital | $-19,932,000 | $-7,132,000 |
| Working Capital | $-25,272,000 | $-8,958,000 |
| Capital Lease Obligations | $1,830,000 | $0 |
| Total Capitalization | $-24,232,000 | $-7,828,000 |
| Additional Paid In Capital | $166,380,000 | $152,183,000 |
| Capital Stock | $3,000 | $2,000 |
| Common Stock | $3,000 | $2,000 |
| Preferred Stock | $0 | $0 |
| Non Current Deferred Revenue | $737,000 | $913,000 |
| Long Term Capital Lease Obligation | $1,292,000 | $0 |
| Current Deferred Revenue | $20,173,000 | $20,838,000 |
| Current Capital Lease Obligation | $538,000 | $0 |
| Current Accrued Expenses | $9,564,000 | $6,464,000 |
| Net PPE | $2,147,000 | $1,357,000 |
| Accumulated Depreciation | $-2,043,000 | $-1,585,000 |
| Gross PPE | $4,190,000 | $2,942,000 |
| Leases | $527,000 | $527,000 |
| Other Properties | $3,663,000 | $2,390,000 |
| Machinery Furniture Equipment | $0 | $25,000 |
| Properties | $0 | $0 |
| Construction In Progress | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-29,209,000 | $-23,466,000 |
| Operating Activities | ||
| Operating Cash Flow | $-29,127,000 | $-22,936,000 |
| Cash Flow From Continuing Operating Activities | $-29,127,000 | $-22,936,000 |
| Operating Gains Losses | - | $-722,000 |
| Investing Activities | ||
| Capital Expenditure | $-82,000 | $-530,000 |
| Investing Cash Flow | $-82,000 | $-530,000 |
| Cash Flow From Continuing Investing Activities | $-82,000 | $-530,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $12,609,000 | $29,715,000 |
| Financing Cash Flow | $14,782,000 | $34,720,000 |
| Cash Flow From Continuing Financing Activities | $14,782,000 | $34,720,000 |
| Net Other Financing Charges | $-1,030,000 | - |
| Net Common Stock Issuance | $12,609,000 | $29,715,000 |
| Common Stock Issuance | $12,609,000 | $29,715,000 |
| Other | ||
| Repayment Of Debt | $-1,800,000 | $0 |
| Issuance Of Debt | $5,000,000 | $5,000,000 |
| Income Tax Paid Supplemental Data | $19,000 | $2,000 |
| End Cash Position | $5,559,000 | $19,986,000 |
| Beginning Cash Position | $19,986,000 | $8,732,000 |
| Changes In Cash | $-14,427,000 | $11,254,000 |
| Proceeds From Stock Option Exercised | $3,000 | $5,000 |
| Net Issuance Payments Of Debt | $3,200,000 | $5,000,000 |
| Net Long Term Debt Issuance | $3,200,000 | $5,000,000 |
| Long Term Debt Payments | $-1,800,000 | $0 |
| Long Term Debt Issuance | $5,000,000 | $5,000,000 |
| Net PPE Purchase And Sale | $-82,000 | $-530,000 |
| Purchase Of PPE | $-82,000 | $-530,000 |
| Change In Working Capital | $-1,299,000 | $10,517,000 |
| Change In Other Working Capital | $-841,000 | $2,149,000 |
| Change In Other Current Liabilities | $-30,000 | $0 |
| Change In Other Current Assets | $104,000 | $56,000 |
| Change In Payables And Accrued Expense | $259,000 | $8,003,000 |
| Change In Accrued Expense | $3,191,000 | $5,349,000 |
| Change In Payable | $-2,932,000 | $2,654,000 |
| Change In Account Payable | $-2,932,000 | $2,654,000 |
| Change In Prepaid Assets | $212,000 | $178,000 |
| Change In Receivables | $-1,003,000 | $131,000 |
| Changes In Account Receivables | $-1,000,000 | $0 |
| Other Non Cash Items | $350,000 | $6,776,000 |
| Stock Based Compensation | $1,479,000 | $2,251,000 |
| Asset Impairment Charge | $227,000 | $0 |
| Depreciation Amortization Depletion | $487,000 | $435,000 |
| Depreciation And Amortization | $487,000 | $435,000 |
| Net Income From Continuing Operations | $-30,371,000 | $-42,193,000 |
| Earnings Losses From Equity Investments | - | $0 |
Fetched: 2026-02-02